In vitro antimetastatic effect of phosphatidylinositol 3-kinase inhibitor ZSTK474 on prostate cancer PC3 cells

International Journal of Molecular Sciences

Volumn 14, Issue 7, 2013, Pages 13577-13591

  Zhao, Wennan ^a   Guo, Wenzhi ^a   Zhou, Qianxiang ^a   Ma, Sheng Nan ^a   Wang, Ran ^a   Qiu, Yuling ^a   Jin, Meihua ^a   Duan, Hong Quan ^a,b   Kong, Dexin ^a,b,c  

^a Inst Medical Pharmaceutical Sciences   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Antimetastasis; Girdin; PC3; Phosphatidylinositol 3 kinase inhibitor; VEGF; ZSTK474

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; VASCULOTROPIN; ENZYME INHIBITOR; TRIAZINE DERIVATIVE; TUMOR PROTEIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER HORMONE THERAPY; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LETHALITY; METASTASIS INHIBITION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOLID TUMOR; TUMOR CELL; UMBILICAL VEIN ENDOTHELIAL CELL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; ENZYMOLOGY; MALE; METABOLISM; METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TUMOR INVASION;

CELL ADHESION; CELL MOVEMENT; ENZYME INHIBITORS; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TRIAZINES;

EID: 84879906110     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140713577     Document Type: Article

References (32)

1. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2, 563-572.
2. Toker, A.; Cantley, L.C. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997, 387, 673-676.
3. Franke, T.F.; Kaplan, D.R.; Cantley, L.C. PI3K: downstream AKTion blocks apoptosis. Cell 1997, 88, 435-437.
4. Kong, D.; Yamori, T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr. Med. Chem. 2009, 16, 2839-2854.
5. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S.M.; Riggins, G.J.; et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304, 554.
6. Kong, D.; Yamori, T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci. 2008, 99, 1734-1740.
7. Kong, D.X.; Yamori, T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol. Sin. 2010, 31, 1189-1197.
8. Yaguchi, S.; Fukui, Y.; Koshimizu, I.; Yoshimi, H.; Matsuno, T.; Gouda, H.; Hirono, S.; Yamazaki, K.; Yamori, T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst. 2006, 98, 545-556.
9. Kong, D.; Yamori, T. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg. Med. Chem. 2012, 20, 1947-1951.
10. Kong, D.; Yamori, T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci. 2007, 98, 1638-1642.
11. Kong, D.; Yaguchi, S.; Yamori, T. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol. Pharm. Bull. 2009, 32, 297-300.
12. Kong, D.; Dan, S.; Yamazaki, K.; Yamori, T. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur. J. Cancer 2010, 46, 1111-1121.
13. Kong, D.; Okamura, M.; Yoshimi, H.; Yamori, T. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. Eur. J. Cancer 2009, 45, 857-865.
14. Toyama, S.; Tamura, N.; Haruta, K.; Karakida, T.; Mori, S.; Watanabe, T.; Yamori, T.; Takasaki, Y. Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice. Arthritis Res. Ther. 2010, 12, R92.
15. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P.J.; Valero, V.; Guzman, M.; Botero, M.L.; Llonch, E.; Atzori, F.; Di Cosimo, S.; et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68, 8022-8030.
16. GraphPad Prism, version 4; Available online: http://www.graphpad.com/scientific-software/prism/ (Accessed on 26, June, 2013).
17. Ridley, A.J.; Schwartz, M.A.; Burridge, K.; Firtel, R.A.; Ginsberg, M.H.; Borisy, G.; Parsons, J.T.; Horwitz, A.R. Cell migration: integrating signals from front to back. Science 2003, 302, 1704-1709.
18. Kitamura, T.; Asai, N.; Enomoto, A.; Maeda, K.; Kato, T.; Ishida, M.; Jiang, P.; Watanabe, T.; Usukura, J.; Kondo, T.; et al. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat. Cell Biol. 2008, 10, 329-337.
19. Jiang, P.; Enomoto, A.; Jijiwa, M.; Kato, T.; Hasegawa, T.; Ishida, M.; Sato, T.; Asai, N.; Murakumo, Y.; Takahashi, M. An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res. 2008, 68, 1310-1318.
20. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161-174.
21. Folkman, J. Angiogenesis: An organizing principle for drug discovery? Nat. Rev. Drug Discov. 2007, 6, 273-286.
22. Jiang, B.H.; Jiang, G.; Zheng, J.Z.; Lu, Z.; Hunter, T.; Vogt, P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001, 12, 363-369.
23. Rini, B.I.; Small, E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 2005, 23, 1028-1043.
24. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev.Cancer 2003, 3, 721-732.
25. Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 1999, 77, 527-543.
26. Ferrara, N.; Gerber, H.P. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001, 106, 148-156.
27. Folkman, J. Angiogenesis. Annu. Rev. Med. 2006, 57, 1-18.
28. Kong, D.; Yamori, T.; Kobayashi, M.; Duan, H. Antiproliferative and antiangiogenic activities of smenospongine, a marine sponge sesquiterpene aminoquinone. Mar. Drugs 2011, 9, 154-161.
29. Lee, H.S.; Seo, E.Y.; Kang, N.E.; Kim, W.K. [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. J. Nutr. Biochem. 2008, 19, 313-319.
30. ImageJ, version 1.47. Available online: http://rsbweb.nih.gov/ij/ (accessed on 26 June 2013).
31. Hsiech, C.Y.; Tsai, P.C.; Tseng, C.H.; Chen, Y.L.; Chang, L.S.; Lin, S.R. Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells. Toxicol. In Vitro. 2013, 27, 1-10.
32. MetaMorph, version 6.3. Available online: http://www.moleculardevices.com/Products/Software/Meta-Imaging-Series/Me taMorph.html (accessed on 26 June 2013).